IL2 and neoplasm: GSVA of significant genes showed higher pathway activity in negatively regulating immune activation (e.g., down‐regulation of interleukin (IL)−2 and type‐1 IFN signalling pathway) in tumour‐invaded TDLN (Figure S7C).